Biophan Technologies Launches German Website; New Website Underscores Company's Commitment to Investor Support and Communication.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTC BB: BIPH - News), a developer of next-generation biomedical technology, announced today it has launched a German language website to serve its large population of investors based in Germany. The announcement was made by Michael Weiner, CEO of Biophan.

Biophan's German website is located at www.biophan-technologies.de. The Company believes it will enhance communication and support of their German and European investor base, and help further raise Biophan's profile in this important marketplace.

"The German market has been a very strong supporter of Biophan, and has shown a keen interest in our nanotechnology innovations," said Michael Weiner, Biophan CEO. "In support of our many shareholders in Germany, we have created a German language website with translations for nearly all pages. We have the highest commitment to our investors, and we want to ensure that key information about Biophan's news and business accomplishments reaches interested parties as efficiently and quickly as possible."

In Germany, Biophan presented recently at the NanoStart Nanostock Day, Nanotech, in Frankfurt. The Company will present on December 4, 2004, at a private alumni reunion of investors, fund managers, and analysts, to be held at the Berlin Stock Exchange.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 21 issued U.S. patents and 71 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.